Information Provided By: 
Fly News Breaks for February 20, 2020
ABUS
Feb 20, 2020 | 08:14 EDT
As reported previously, Baird analyst Madhu Kumar initiated coverage of Arbutus Biopharma with an Outperform rating and $8 price target. The analyst also designated it as a Fresh Pick as relative to other clinical HBV RNAi firms, the shares remain undervalued.
News For ABUS From the Last 2 Days
There are no results for your query ABUS
